An Investigational Scan (68Ga-PSMA-11 PET/CT) for the Imaging of Prostate Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Biochemically Recurrent Prostate Carcinoma
- Castration-Resistant Prostate Carcinoma
- Metastatic Prostate Carcinoma
- Prostate Adenocarcinoma
- Stage IV Prostate Cancer AJCC v8
- Stage IVA Prostate Cancer AJCC v8
- Stage IVB Prostate Cancer AJCC v8
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Diagnostic
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Only males
Description
OUTLINE: Patients receive gallium Ga 68-labeled PSMA-11 intravenously (IV) then undergo PET/CT over 2-3 minutes per bed position at baseline. Patients receiving systemic therapy undergo an additional 68Ga-PSMA-11 PET/CT scan 6 weeks after initiating therapy. After the completion of study, patients a...
OUTLINE: Patients receive gallium Ga 68-labeled PSMA-11 intravenously (IV) then undergo PET/CT over 2-3 minutes per bed position at baseline. Patients receiving systemic therapy undergo an additional 68Ga-PSMA-11 PET/CT scan 6 weeks after initiating therapy. After the completion of study, patients are followed for up to 5 years.
Tracking Information
- NCT #
- NCT04777071
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Delphine L. Chen, M.D. Fred Hutch/University of Washington Cancer Consortium
Get Well Soon